GILD Research and Charts

GILD - Gilead Sciences Inc (Healthcare: Drug Manufacturers - General)

Projected Earnings Date: 2025-07-24 (Delayed quote data 2025-07-11)

Last 109.64	Change ⇓ -4.90 (-4.28%)	Volume 6,114,986
	Open 113.75	High 113.81	Low 109.45

8EMA (Daily) 111.47	40EMA (Daily) 109.09	50EMA (Daily) 108.59	STO (Daily) 83.295	MACD Hist (Daily) 0.301
8EMA (Weekly) 109.308	40EMA (Weekly) 100.55	50EMA (Weekly) 98.04	STO (Weekly) 76.736	MACD Hist (Weekly) -0.417


Company Profile
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.